These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 1372464)

  • 1. Treatment and prognosis of orbital non-Hodgkin's lymphomas.
    Platanias LC; Putterman AM; Vijayakumar S; Recant W; Weichselbaum RR; Bitran JD
    Am J Clin Oncol; 1992 Feb; 15(1):79-83. PubMed ID: 1372464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
    Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
    Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin's lymphoma.
    McMaster ML; Greer JP; Wolff SN; Johnson DH; Greco FA; Stein RS; Cousar JB; Flexner JM; Hainsworth JD
    Cancer; 1991 Jul; 68(2):233-41. PubMed ID: 1712662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
    Longo DL; Duffey PL; Jaffe ES; Raffeld M; Hubbard SM; Fisher RI; Wittes RE; DeVita VT; Young RC
    J Clin Oncol; 1994 Oct; 12(10):2153-9. PubMed ID: 7523607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies.
    Anderson KC; Skarin AT; Rosenthal DS; MacIntyre JM; Pinkus GS; Case DC; Leonard RC; Canellos GP
    Cancer Treat Rep; 1984 Nov; 68(11):1343-50. PubMed ID: 6209007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
    Miller TP; Dana BW; Weick JK; Jones SE; Coltman CA; Dahlberg S; Fisher RI
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):17-22. PubMed ID: 2456619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The place of third-generation regimens in the treatment of adult aggressive non-Hodgkin's lymphoma.
    Armitage JO
    Ann Oncol; 1991 Jan; 2 Suppl 1():37-41. PubMed ID: 1710488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
    Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
    Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mediastinal large-B-cell lymphoma with sclerosis: a clinical study of 21 patients.
    Todeschini G; Ambrosetti A; Meneghini V; Pizzolo G; Menestrina F; Chilosi M; Benedetti F; Veneri D; Cetto GL; Perona G
    J Clin Oncol; 1990 May; 8(5):804-8. PubMed ID: 1692089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas.
    Mazza P; Zinzani PL; Martelli M; Fiacchini M; Bocchia M; Pileri S; Falini B; Martelli MF; Amadori S; Papa G
    Leuk Lymphoma; 1995 Feb; 16(5-6):457-63. PubMed ID: 7540460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.
    Miller TP; Dahlberg S; Weick JK; Files JC; Eyre HJ; Pendergrass KB; Fisher RI
    J Clin Oncol; 1990 Dec; 8(12):1951-8. PubMed ID: 1700079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide and dexamethasone (ACOMED) followed by involved field radiotherapy induces high remission rates and durable long-term survival in patients with aggressive malignant non-Hodgkin's lymphomas: long-term follow-up of a pilot study.
    Rödel S; Engert A; Diehl V; Reiser M
    Leuk Lymphoma; 2005 Dec; 46(12):1729-34. PubMed ID: 16353313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-Hodgkin's lymphoma in Saudi Arabia: prognostic factors and an analysis of the outcome of combination chemotherapy only, for both localized and advanced disease.
    Ibrahim EM; Satti MB; Al-Idrissi HY; Al-Mulhim FA; Abssod GH; Abdel Jabar A
    Eur J Cancer Clin Oncol; 1988 Mar; 24(3):391-401. PubMed ID: 2454821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cooperative study on ProMACE-CytaBOM in aggressive non-Hodgkin's lymphomas.
    Cassi E; Butti C; Baldini L; Pisoni GB; Ceriani A; Confalonieri C; Scandolaro L; De Paoli A; Lombardi F; Montalbetti L
    Leuk Lymphoma; 1994 Mar; 13(1-2):111-8. PubMed ID: 7517742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas.
    Schneider AM; Straus DJ; Schluger AE; Lowenthal DA; Koziner B; Lee BJ; Wong G; Clarkson BD
    J Clin Oncol; 1990 Jan; 8(1):94-102. PubMed ID: 1688617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas.
    Winter JN; Andersen J; Variakojis D; Gordon LI; Fisher RI; Oken MM; Neiman RS; Jiang S; Bauer KD
    Blood; 1996 Nov; 88(10):3919-25. PubMed ID: 8916958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stage I non-Hodgkin's lymphoma treated with doxorubicin-containing chemotherapy with or without radiotherapy.
    Villikka K; Muhonen T; Ristamäki R; Teerenhovi L; Joensuu H
    Acta Oncol; 1997; 36(6):619-24. PubMed ID: 9408153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.